User profiles for Michael Sigouros

Michael Sigouros

Weill Cornell Medicine
Verified email at med.cornell.edu
Cited by 1488

[HTML][HTML] Distinct classes of complex structural variation uncovered across thousands of cancer genome graphs

…, EM Adney, A Shaiber, Z Gajic, M Sigouros… - Cell, 2020 - Elsevier
Cancer genomes often harbor hundreds of somatic DNA rearrangement junctions, many of
which cannot be easily classified into simple (eg, deletion) or complex (eg, chromothripsis) …

[HTML][HTML] Patient derived organoids to model rare prostate cancer phenotypes

…, M Benelli, WR Karthaus, J Hess, M Sigouros… - Nature …, 2018 - nature.com
A major hurdle in the study of rare tumors is a lack of existing preclinical models. Neuroendocrine
prostate cancer is an uncommon and aggressive histologic variant of prostate cancer …

[HTML][HTML] Clinical features of neuroendocrine prostate cancer

…, C Oromendia, KW Eng, R Bareja, M Sigouros… - European journal of …, 2019 - Elsevier
Background Neuroendocrine prostate cancer (NEPC) is an aggressive variant of prostate
cancer that may arise de novo or in patients previously treated with hormonal therapies for …

[HTML][HTML] Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer

…, V Conteduca, N Casiraghi, M Sigouros… - The Journal of …, 2020 - Am Soc Clin Investig
Loss of androgen receptor (AR) signaling dependence occurs in approximately 15%–20%
of advanced treatment-resistant prostate cancers, and this may manifest clinically as …

[HTML][HTML] Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer

…, R Carelli, F Khani, M Bakht, M Sigouros… - Nature …, 2021 - nature.com
Despite advances in the development of highly effective androgen receptor (AR)-directed
therapies for the treatment of men with advanced prostate cancer, acquired resistance to such …

Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer

…, V Conteduca, E Dardenne, M Sigouros… - Science translational …, 2019 - science.org
Histologic transformation to small cell neuroendocrine prostate cancer occurs in a subset of
patients with advanced prostate cancer as a mechanism of treatment resistance. …

Impact of therapy on genomics and transcriptomics in high-risk prostate cancer treated with neoadjuvant docetaxel and androgen deprivation therapy

…, M Annala, EW Warner, K Beja, M Sigouros… - Clinical Cancer …, 2017 - AACR
Purpose: The combination of docetaxel chemotherapy and androgen deprivation therapy (ADT)
has become a standard treatment for patients with metastatic prostate cancer. The …

Extracellular matrix in synthetic hydrogel‐based prostate cancer organoids regulate therapeutic response to EZH2 and DRD2 inhibitors

…, H Pan, M Asad, ML Martin, M Sigouros… - Advanced …, 2022 - Wiley Online Library
Following treatment with androgen receptor (AR) pathway inhibitors, ≈20% of prostate cancer
patients progress by shedding their AR‐dependence. These tumors undergo epigenetic …

SLFN11 expression in advanced prostate cancer and response to platinum-based chemotherapy

…, J Hess, R Bareja, PJ Vlachostergios, M Sigouros… - Molecular cancer …, 2020 - AACR
Expression of the DNA/RNA helicase schlafen family member 11 (SLFN11) has been identified
as a sensitizer of tumor cells to DNA-damaging agents including platinum chemotherapy. …

Detecting neuroendocrine prostate cancer through tissue-informed cell-free DNA methylation analysis

…, V Conteduca, O Elemento, J Auh, M Sigouros… - Clinical Cancer …, 2022 - AACR
Purpose: Neuroendocrine prostate cancer (NEPC) is a resistance phenotype that emerges
in men with metastatic castration-resistant prostate adenocarcinoma (CR-PRAD) and has …